Improvement of IFNγ ELISPOT performance following overnight resting of frozen PBMC samples confirmed through rigorous statistical analysis

Cells

Volumn 4, Issue 1, 2015, Pages

  Santos, Radleigh ^a   Buying, Alcinette ^a   Sabri, Nazila ^a   Yu, John ^b,c   Gringeri, Anthony ^c   Bender, James ^c,e   Janetzki, Sylvia ^d   Pinilla, Clemencia ^a   Judkowski, Valeria A ^a  

^a TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c ImmunoCellular Therapeutics Ltd   (United States)

^d Zellnet Consulting   (United States)

^e Lion Biotechnologies   (United States)

Author keywords

IFN ELISPOT; Immune monitoring; Overnight resting; PBMC

Indexed keywords

GAMMA INTERFERON; HLA A2 ANTIGEN;

ARTICLE; CD8+ T LYMPHOCYTE; CELL VIABILITY; CONTROLLED STUDY; CRYOPRESERVATION; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; INFLUENZA VIRUS; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL;

EID: 85050578223     PISSN: None     EISSN: 20734409     Source Type: Journal    
DOI: 10.3390/cells4010001     Document Type: Article

References (33)

1. Janetzki, S.; Romero, P.; Roederer, M.; Bolton, D.; Jandus, C. Immune Monitoring Design within the Developmental Pipeline for an Immunotherapeutic or Preventive Vaccine. In Vaccinology: Principles and Practice; Morrow, W. J. W., Sheikh, N. A., Schmidt, C. S., Davies, D. H., Eds; Wiley-Blackwell: Hoboken, NJ, USA, 2012; pp. 419-440.
2. Mallone, R.; Mannering, S. I.; Brooks-Worrell, B. M.; Durinovic-Bello, I.; Cilio, C. M.; Wong, F. S.; Schloot, N. C. Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive cell responses: Position statement of the T-cell workshop committee of the immunology of t diabetes society. Clin. Exp. Immunol. 2011, 163, 33-49.
3. Bull, M.; Lee, D.; Stucky, J.; Chiu, Y. L.; Rubin, A.; Horton, H.; McElrath, M. J. Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J. Immunol. Methods 2007, 322, 57-69.
4. Kierstead, L. S.; Dubey, S.; Meyer, B.; Tobery, T. W.; Mogg, R.; Fernandez, V. R.; Long, R.; Guan, L.; Gaunt, C.; Collins, K.; et al. Enhanced rates and magnitude of immune responses detected against an hiv vaccine: Effect of using an optimized process for isolating pbmc. AIDS Res. Hum. Retroviruses 2007, 23, 86-92.
5. Afonso, G.; Scotto, M.; Renand, A.; Arvastsson, J.; Vassilieff, D.; Cilio, C. M.; Mallone, R. Critical parameters in blood processing for t-cell assays: Validation on ELISPOT and tetramer platforms. J. Immunol. Methods 2010, 359, 28-36.
6. Olson, W. C.; Smolkin, M. E.; Farris, E. M.; Fink, R. J.; Czarkowski, A. R.; Fink, J. H.; Chianese-Bullock, K. A.; Slingluff, C. L., Jr. Shipping blood to a central laboratory in multicenter clinical trials: Effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function. J. Translat. Med. 2011, 9, 26.
7. McKenna, K. C.; Beatty, K. M.; Vicetti Miguel, R.; Bilonick, R. A. Delayed processing of blood increases the frequency of activated CD11b+ CD15+ granulocytes which inhibit T-cell function. J. Immunol. Methods 2009, 341, 68-75.
8. Filbert, H.; Attig, S.; Bidmon, N.; Renard, B. Y.; Janetzki, S.; Sahin, U.; Welters, M. J.; Ottensmeier, C.; van der Burg, S. H.; Gouttefangeas, C.; et al. Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols. Cancer Immunol. Immunother. 2013, 62, 615-627.
9. Smith, J. G.; Liu, X.; Kaufhold, R. M.; Clair, J.; Caulfield, M. J. Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin. Diagnost. Lab. Immunol. 2001, 8, 871-879.
10. Janetzki, S.; Price, L.; Britten, C. M.; van der Burg, S. H.; Caterini, J.; Currier, J. R.; Ferrari, G.; Gouttefangeas, C.; Hayes, P.; Kaempgen, E.; et al. Performance of serum-supplemented and serum free media in ifngamma ELISPOT assays for human T-cells. Cancer Immunol. Immunother. 2010, 59, 609-618.
11. Smith, J. G.; Joseph, H. R.; Green, T.; Field, J. A.; Wooters, M.; Kaufhold, R. M.; Antonello, J.; Caulfield, M. J. Establishing acceptance criteria for cell-mediated-immunity assays using frozen peripheral blood mononuclear cells stored under optimal and suboptimal conditions. Clin. Vaccine Immunol. 2007, 14, 527-537.
12. Lenders, K.; Ogunjimi, B.; Beutels, P.; Hens, N.; van Damme, P.; Berneman, Z. N.; van Tendeloo, V. F.; Smits, E. L. The effect of apoptotic cells on virus-specific immune responses detected using IFNγ ELISPOT. J. Immunol. Methods 2010, 357, 51-54.
13. Romer, P. S.; Berr, S.; Avota, E.; Na, S. Y.; Battaglia, M.; ten Berge, I.; Einsele, H.; Hunig, T. Preculture of pbmcs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood 2011, 118, 6772-6782.
14. Janetzki, S.; Panageas, K. S.; Ben-Porat, L.; Boyer, J.; Britten, C. M.; Clay, T. M.; Kalos, M.; Maecker, H. T.; Romero, P.; Yuan, J.; et al. Results and harmonization guidelines from two largescale international ELISPOT proficiency panels conducted by the cancer vaccine consortium (cvc/svi). Cancer Immunol. Immunother. 2008, 57, 303-315.
15. Britten, C. M.; Gouttefangeas, C.; Welters, M. J.; Pawelec, G.; Koch, S.; Ottensmeier, C.; Mander, A.; Walter, S.; Paschen, A.; Muller-Berghaus, J.; et al. The cimt-monitoring panel: A two-step approach to harmonize the enumeration of antigen-specific CD8+ t lymphocytes by structural and functional assays. Cancer Immunol. Immunother. 2008, 57, 289-302.
16. Van der Burg, S. H.; Kalos, M.; Gouttefangeas, C.; Janetzki, S.; Ottensmeier, C.; Welters, M. J.; Romero, P.; Britten, C. M.; Hoos, A. Harmonization of immune biomarker assays for clinical studies. Sci. Transl. Med. 2011, 3, 108ps44.
17. Janetzki, S.; Britten, C. M. The impact of harmonization on ELISPOT assay performance. Methods Mol. Biol. 2012, 792, 25-36.
18. Kutscher, S.; Dembek, C. J.; Deckert, S.; Russo, C.; Korber, N.; Bogner, J. R.; Geisler, F.; Umgelter, A.; Neuenhahn, M.; Albrecht, J.; et al. Overnight resting of pbmc changes functional signatures of antigen specific T-cell responses: Impact for immune monitoring within clinical trials. PLoS One 2013, 8, e76215.
19. Moodie, Z.; Price, L.; Gouttefangeas, C.; Mander, A.; Janetzki, S.; Lower, M.; Welters, M. J.; Ottensmeier, C.; van der Burg, S. H.; Britten, C. M. Response definition criteria for ELISPOT assays revisited. Cancer Immunol. Immunother. 2010, 59, 1489-1501.
20. Britten, C. M.; Janetzki, S.; Butterfield, L. H.; Ferrari, G.; Gouttefangeas, C.; Huber, C.; Kalos, M.; Levitsky, H. I.; Maecker, H. T.; Melief, C. J.; et al. T-cell assays and miata: The essential minimum for maximum impact. Immunity 2012, 37, 1-2.
21. Currier, J. R.; Kuta, E. G.; Turk, E.; Earhart, L. B.; Loomis-Price, L.; Janetzki, S.; Ferrari, G.; Birx, D. L.; Cox, J. H. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J. Immunol. Methods 2002, 260, 157-172.
22. Santos, R.; Buying A.; Sabri, N.; Appel, J.; Yu, J.; Gringeri, A.; Bender, J.; Janetzki, S.; Pinilla, C.; Judkowski, V.; et al. Torrey Pines Institute for Molecular Studies, Port St. Lucie, FL, USA. Unpublished work, 2014.
23. Stefanova, I.; Dorfman, J. R.; Germain, R. N. Self-recognition promotes the foreign antigen sensitivity of naive T lymphocytes. Nature 2002, 420, 429-434.
24. Garcia, K. C.; Adams, J. J.; Feng, D.; Ely, L. K. The molecular basis of tcr germline bias for mhc is surprisingly simple. Nat. Immunol. 2009, 10, 143-147.
25. Randriamampita, C.; Boulla, G.; Revy, P.; Lemaitre, F.; Trautmann, A. T-cell adhesion lowers the threshold for antigen detection. Eur. J. Immunol. 2003, 33, 1215-1223.
26. Fischer, J.; Hackenberg, S.; Grigoleit, G. U.; Stevanovic, S.; Huenig, T. Resetting circulating CD8 T-cells to a tissue-like status permits sensitive detection of their responses to virus-and tumorassociated antigens. Proceedings of the 12th Annual Meeting of the Association for Immunotherapy of Cancer, Mainz, Germany, 6-8 May 2014.
27. Kuerten, S.; Batoulis, H.; Recks, M. S.; Karacsony, E.; Zhang, W.; Subbramanian, R. A.; Lehmann, P. V. Resting of Cryopreserved PBMC Does Not Generally Benefit the Performance of Antigen-Specific T-cell ELISPOT Assays. Cells 2012, 1, 409-427.
28. Moodie, Z.; Huang, Y.; Gu, L.; Hural, J.; Self, S. G. Statistical positivity criteria for the analysis of ELISPOT assay data in HIV-1 vaccine trials. J. Immunol. Methods 2006, 315, 121-132.
29. Malyguine, A.; Strobl, S. L.; Shafer-Weaver, K. A.; Ulderich, T.; Troke, A.; Baseler, M.; Kwak, L. W.; Neelapu, S. S. A modified human ELISPOT assay to detect specific responses to primary tumor cell targets. J. Translat. Med. 2004, 2, 9.
30. Gill, D. K.; Huang, Y.; Levine, G. L.; Sambor, A.; Carter, D. K.; Sato, A.; Kopycinski, J.; Hayes, P.; Hahn, B.; Birungi, J.; et al. Equivalence of ELISPOT assays demonstrated between major HIV network laboratories. PLoS One. 2010, 5, e14330.
31. Gorse, G. J.; Baden, L. R.; Wecker, M.; Newman, M. J.; Ferrari, G.; Weinhold, K. J.; Livingston, B. D.; Villafana, T. L.; Li, H.; Noonan, E.; Russell, N. D. Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. Vaccine 2008, 26, 215-223.
32. Chudley, L.; McCann, K. J.; Coleman, A.; Cazaly, A. M.; Bidmon, N.; Britten, C. M.; van der Burg, S. H.; Gouttefangeas, C.; Jandus, C.; Laske, K.; et al. Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8 T-cells with detection by ELISPOT and hla-multimer staining. Cancer Immunol. Immunother. 2014, 63, 1199-1211.
33. Gajewski, T. F.; Schreiber, H.; Fu, Y. X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 2013, 14, 1014-1022.